Key result
Quarterly echocardiography during HER2-directed therapy is not cost-effective compared to less frequent surveillance.
Why the study?
Quarterly echocardiographic surveillance during trastuzumab-based HER2-directed therapy was established in the early 2000s, and lower LVEF decline rates with newer regimens warrant re-evaluation of the justification for frequent cardiac surveillance.
Does quarterly echocardiographic surveillance improve cost-effectiveness and detection of cardiac dysfunction compared to less frequent imaging in patients with breast cancer receiving trastuzumab-based HER2-directed therapies?
Meta-Analysis (n=37,847)
Does quarterly echocardiographic surveillance improve cost-effectiveness and detection of cardiac dysfunction compared to less frequent imaging in patients with breast cancer receiving trastuzumab-based HER2-directed therapies?
Routine quarterly echocardiography is not cost-effective for lower-risk patients receiving HER2-directed breast cancer therapies, supporting de-escalation to baseline-only or 6-month surveillance depending on the regimen and stage.
Answers are grounded in this paper and cite their sources.
Supports de-escalated cardiac monitoring in trastuzumab-treated breast cancer; challenges intensive surveillance guidelines with cost-effectiveness data.
BACKGROUND: Quarterly echocardiographic surveillance during trastuzumab-based human epidermal growth factor receptor 2-directed therapy was established in the early 2000s. With lower left ventricular ejection fraction (LVEF) decline rates with newer regimens, the justification for frequent cardiac surveillance warrants re-evaluation. MATERIALS AND METHODS: We carried out a systematic review and single-arm meta-analysis of clinical trials of patients receiving trastuzumab, trastuzumab emtansine (T-DM1), or trastuzumab deruxtecan (T-DXd), using pooled estimates of study-reported cardiac dysfunction, predominantly decreased LVEF, to evaluate echocardiographic surveillance strategies. For early-stage disease (12-month treatment duration), strategies evaluated included baseline echocardiography plus imaging at 6 months, baseline plus imaging at 6 and 12 months, and baseline plus imaging at 3, 6, 9, and 12 months. For metastatic disease (continuous treatment), strategies included baseline echocardiography plus annual imaging, baseline plus imaging every 6 months, and baseline plus imaging every 3 months. RESULTS: Fifty-seven studies conducted from 1999 to 2026 (37 847 patients) were included. Pooled rates of study-reported cardiac dysfunction, predominantly decreased LVEF, were 4.5%, 1.7%, and 1.4% for trastuzumab, T-DXd, and T-DM1, respectively, in early-stage disease, and 7.7%, 3.3%, and 2.3%, respectively, in metastatic disease; grade 3 events were rare. At a willingness-to-pay threshold of $120 000/quality-adjusted life year (QALY), baseline echocardiography plus one follow-up study at 6 months was preferred for early-stage trastuzumab, whereas baseline-only imaging was preferred for early-stage T-DM1 and T-DXd. Monitoring every 3 months was not cost-effective for any early-stage regimen, with incremental cost-effectiveness ratios (ICERs) of $12 974 923/QALY for trastuzumab, $3 033 636/QALY for T-DM1, and $4 388 134/QALY for T-DXd. In metastatic disease, baseline-only imaging was preferred for all three regimens; annual monitoring exceeded the willingness-to-pay threshold for trastuzumab, T-DM1, and T-DXd, with ICERs of $191 781/QALY, $537 175/QALY, and $353 098/QALY, respectively. CONCLUSIONS: Echocardiography every 3 months was not cost-effective for any regimen or disease setting. Monitoring should be regimen- and setting-specific, with prospective validation of less intensive strategies. These findings are only applicable to lower-risk, trial-eligible patients.
No takes yet. Share an insight, caveat, or question.
Menezes et al. (2026) conducted a meta-analysis in Breast cancer receiving trastuzumab-based HER2-directed therapies (n=37,847). Echocardiographic surveillance every 3 months (quarterly monitoring) vs. Less frequent echocardiographic surveillance (baseline only, 6-month, or annual imaging) was evaluated on Study-reported cardiac dysfunction (predominantly decreased LVEF) and incremental cost-effectiveness ratio (ICER) per QALY. Quarterly echocardiography during HER2-directed therapy was not cost-effective in any setting, with early-stage ICERs of $3.0M-$13.0M/QALY vs less frequent imaging.
Synapse has enriched 10 related papers. Consider them for comparative context: